Business Wire

Galderma receives a positive outcome through the European Decentralised Procedure for AKLIEF® (trifarotene 50 mcg/g cream), the first new retinoid molecule for acne in the European Union in 25 years1

20.12.2019 11:00:00 EET | Business Wire | Press release

Share

Galderma today announced that AKLIEF® (trifarotene 50 mcg/g cream) has concluded its European decentralised procedure resulting in the approval of its summary of product characteristics, package leaflet, and labelling, by all involved European member states. Each of the 16 concerned member states will now issue individual national marketing authorisations for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. Once approved, trifarotene 50 mcg/g cream will be the first new retinoid molecule launched in the European Union in 25 years.1

“Although retinoids are the cornerstone of acne treatment, there have been few significant advances or developments in decades,” said Professor Thomas Dirschka, University of Witten-Herdecke, Germany. “It is encouraging to see innovative approaches to tackling one of the most common and frustrating skin diseases.”

“Truncal acne can affect almost half of those with facial acne. It often goes under-reported and underdiagnosed, despite a desire from patients to have it treated,” said Professor Jerry Tan, University of Western Ontario, Windsor, ON, Canada. “To date, there has been a lack of scientific evidence on the management of truncal acne and as such, it is important to investigate new treatment options that specifically address this unmet need.”

Trifarotene 50 mcg/g cream is the first treatment to selectively target retinoic acid receptor gamma (RAR-γ), the most common RAR found in the skin.2,3,4 Trifarotene 50 mcg/g cream was assessed by regulators on data from two large, randomised Phase III clinical trials (PERFECT 1 & 2). Data have demonstrated that the systemic exposure of trifarotene 50 mcg/g cream is low as it is rapidly metabolised in the liver, with a half-life of just five minutes.3 Therefore, as well as treating facial acne, it can be used on large body surface areas of the trunk.3

“Acne can severely impact the quality of life and psychological well-being of those who suffer from it. The approval of AKLIEF® will provide patients across Europe with a next-generation retinoid cream that has been shown to be fast and effective at treating acne on both the face and trunk,” said Dr Thibaud Portal, Galderma Global Vice President of Prescription Medicines. “This underscores Galderma’s commitment to providing innovative solutions for the most common and frustrating skin diseases.”

Trifarotene 50 mcg/g cream has been shown to significantly reduce inflammatory lesions as early as two weeks on the face and four weeks on the back, shoulders and chest compared with vehicle (control) (p<0.001).2 Trifarotene 50 mcg/g cream was well tolerated on the face and trunk. Treatment-related adverse events included mild-to-moderate application site reactions, such as skin irritation, mainly characterised by scaling, dryness, erythema and burning/stinging.2

-END-

About Acne
Acne is one of the most common skin disorders and affects approximately 70 million people across Europe.5 Acne can occur on the face and trunk (shoulders, back and chest)6,7 and it is estimated that around half of people with facial acne also have truncal acne.7 Despite the clear need for treatments that target both facial and truncal acne, there has been a lack of scientific evidence on the management of truncal acne, with the majority of studies focusing on the treatment of facial acne alone.8,9

About AKLIEF®
In the European Union, AKLIEF ® (trifarotene 50 mcg/g cream) is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. It is the only topical retinoid that specifically targets retinoic acid receptor gamma (RAR-γ), the most common RAR in the skin.3,4 National marketing authorisations across concerned European member states will follow in 2020.

AKLIEF ® received approval from the US Food and Drug Administration (FDA) in October 2019.10 It also received approval from Health Canada in November 2019.11

About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com

References

  1. EMA. List of European Union reference dates frequency of submission of periodic safety update reports. Available at https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/periodic-safety-update-reports-psurs (Last access December 2019)
  2. Tan J, et al. J Am Acad Dermatol 2019;80(6):1691–9.
  3. Aubert J, et al. Br J Dermatol 2018;179:442–56.
  4. Fisher GJ, et al. J Biol Chem 1994;269(32):20629–35.
  5. Hay RJ, et al. J Invest Dermatol 2014;134(6 Suppl 1):S2.
  6. Dréno B, et al. J Eur Acad Dermatol Venereol 2015;291096-1106.
  7. Del Rosso JQ, et al. J Drugs Dermatol 2007;6(6):597–600.
  8. Liu CW & Tan J. Skin Therapy Lett 2017;12.
  9. Asai Y, et al. CMAJ 2016;188:118–26.
  10. FDA. Approval of Aklief. Available at: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019 (Last access December 2019)
  11. Health Canada. Approval of Aklief. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/register-innovative-drugs/register.html (Last access December 2019)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Sébastien Cros
Head of Corporate Communications
media@galderma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International’s Alipay+ and The New York Liberty Celebrate Season of Sustainability Impact on Community, Environmental and Youth Empowerment16.11.2026 06:08:00 EET | Press release

Ant International’s Alipay+, a leading cross-border fintech services platform, and the WNBA’s New York Liberty, today announced the results of their joint sustainability initiatives for the season. Marking the first season of the multi-year collaboration, Alipay+ and the New York Liberty planted a total of 219 trees — one for every three-pointer made by the New York Liberty and Alipay+ in-game fan contestants during home games at Barclays Center this season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115082353/en/ Students celebrate during the inaugural Liberty NBA Math Hoops Regional Tournament. In addition to the on-court tree-planting pledge, the partners concluded their fan-driven Sneaker Drive, collecting 650 pairs of shoes to support environmental conservation and global micro-entrepreneurship. In November, they also concluded the inaugural Liberty NBA Math Hoops Regional Tournament presented by Alipay+ and Lear

CORRECTING and REPLACING Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 19:10:00 EET | Press release

Please replace the release issued Nov. 12, 2026, at 11:00 p.m. PT/Nov. 13, 2026, at 2:00 a.m. ET with the following corrected version due to multiple revisions in the third paragraph. This release has been updated to ensure the accuracy of certain references in the original version. The updated release reads: YAMAHA TO ACQUIRE DISGUISE, EXPANDING ITS CAPABILITIES IN INTEGRATED AUDIO, VIDEO, LIGHTING AND MEDIA Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into soft

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 18:32:00 EET | Press release

VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware of the promotion and sale of vehicles that it believes were produced in violation of its intellectual property rights. White s.r.o. therefore decided to take direct action in China, entrusting the protection of its rights to Shanghai-based

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 17:53:00 EET | Press release

LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and CEO of LangChain. "Every company should be free to choose the best models for its needs, control its data a

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 14:00:00 EET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurrent platform is the right foundation for that. Operational orchestration builds on it by connecting planning, decisions and ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye